According to InvestingPro analysis, the company stands as a prominent ... This readout is viewed as a significant potential catalyst for Vertex's stock, as success in chronic pain could ...
Vertex Pharmaceuticals Inc. closed 18.83% below its 52-week high of $519.88, which the company achieved on November 8th.
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Vertex stock plummeted Thursday after the ... comparison between suzetrigine and a placebo. Further, ad hoc analysis showed there was "variability in the placebo response across study sites ...
Vertex Securities Ltd share price was down ... All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.
Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...